ID   OCI-Ly4
AC   CVCL_8801
SY   OCI-LY4; OCI-LY-4; OCI-Ly 4; Ly4; LY4
DR   cancercelllines; CVCL_8801
DR   Cosmic; 1517648
DR   Cosmic; 1541902
DR   Cosmic; 1636684
DR   Cosmic; 2276330
DR   GEO; GSM380134
DR   GEO; GSM552452
DR   GEO; GSM1035332
DR   GEO; GSM1374788
DR   IARC_TP53; 6447
DR   Progenetix; CVCL_8801
DR   Wikidata; Q54931774
RX   PubMed=3567358;
RX   PubMed=8574164;
RX   PubMed=11807979;
RX   PubMed=15126345;
RX   PubMed=19278952;
RX   PubMed=20628145;
WW   http://www.innovationbridge.com/uhn/diffuse-large-b-cell-lymphoma-cell-lines?categories=32&communities=5&forums=&organizations=&tags=
CC   From: Ontario Cancer Institute (OCI); Toronto; Canada.
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>T); ClinVar=VCV000634770; Zygosity=Unspecified (PubMed=8574164).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=8574164).
CC   Omics: Array-based CGH.
CC   Omics: CNV analysis.
CC   Omics: miRNA expression profiling.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
DI   NCIt; C8851; Diffuse large B-cell lymphoma
DI   ORDO; Orphanet_544; Diffuse large B-cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   21Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 05-10-23; Version: 23
//
RX   PubMed=3567358; DOI=10.1182/blood.V69.5.1307.1307;
RA   Tweeddale M.E., Lim B., Jamal N., Robinson J., Zalcberg J.R.,
RA   Lockwood G., Minden M.D., Messner H.A.;
RT   "The presence of clonogenic cells in high-grade malignant lymphoma: a
RT   prognostic factor.";
RL   Blood 69:1307-1314(1987).
//
RX   PubMed=8574164; DOI=10.3109/10428199509059672;
RA   Chang H., Blondal J.A., Benchimol S., Minden M.D., Messner H.A.;
RT   "p53 mutations, c-myc and bcl-2 rearrangements in human non-Hodgkin's
RT   lymphoma cell lines.";
RL   Leuk. Lymphoma 19:165-171(1995).
//
RX   PubMed=11807979; DOI=10.1002/gcc.10025;
RA   Mehra S., Messner H.A., Minden M.D., Chaganti R.S.K.;
RT   "Molecular cytogenetic characterization of non-Hodgkin lymphoma cell
RT   lines.";
RL   Genes Chromosomes Cancer 33:225-234(2002).
//
RX   PubMed=15126345; DOI=10.1158/0008-5472.CAN-03-3773;
RA   Ota A., Tagawa H., Karnan S., Tsuzuki S., Karpas A., Kira S.,
RA   Yoshida Y., Seto M.;
RT   "Identification and characterization of a novel gene, C13orf25, as a
RT   target for 13q31-q32 amplification in malignant lymphoma.";
RL   Cancer Res. 64:3087-3095(2004).
//
RX   PubMed=19278952; DOI=10.1182/blood-2009-01-202028;
RA   Li C., Kim S.-W., Rai D., Bolla A.R., Adhvaryu S., Kinney M.C.,
RA   Robetorye R.S., Aguiar R.C.T.;
RT   "Copy number abnormalities, MYC activity, and the genetic fingerprint
RT   of normal B cells mechanistically define the microRNA profile of
RT   diffuse large B-cell lymphoma.";
RL   Blood 113:6681-6690(2009).
//
RX   PubMed=20628145; DOI=10.1182/blood-2010-05-282780;
RA   Green M.R., Monti S., Rodig S.J., Juszczynski P., Currie T.,
RA   O'Donnell E., Chapuy B., Takeyama K., Neuberg D., Golub T.R.,
RA   Kutok J.L., Shipp M.A.;
RT   "Integrative analysis reveals selective 9p24.1 amplification,
RT   increased PD-1 ligand expression, and further induction via JAK2 in
RT   nodular sclerosing Hodgkin lymphoma and primary mediastinal large
RT   B-cell lymphoma.";
RL   Blood 116:3268-3277(2010).
//